CrashWhen

EBS: It's pretty bad when you underperform TNXP

Long
CrashWhen Mis à jour   
NYSE:EBS   Emergent Biosolutions, Inc.
Considering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal.
EBS was never a "squeeze" play because it's already worth a billion dollars. Additionally, I don't believe monkey pox is a serious pandemic regardless of what WHO says. EBS still has a pipeline of drugs that generates revenue and profit. With or without Monkey Pox, EBS should see $50-$60 (fibs) imo.
Commentaire:
Terrible miss on earnings with lowered guidance. More accumulation here.
Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.